|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
EBSCO_ocn841234000 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130430s2012 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d E7B
|d YDXCP
|d OCLCF
|d EBLCP
|d OCLCQ
|d VTS
|d AU@
|d STF
|d OCLCQ
|d K6U
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9781619424067
|q (electronic bk.)
|
| 020 |
|
|
|a 1619424061
|q (electronic bk.)
|
| 020 |
|
|
|z 9781619424050
|
| 020 |
|
|
|z 1619424053
|
| 029 |
1 |
|
|a AU@
|b 000051829505
|
| 029 |
1 |
|
|a DEBBG
|b BV042793269
|
| 029 |
1 |
|
|a DEBSZ
|b 472786199
|
| 035 |
|
|
|a (OCoLC)841234000
|
| 050 |
|
4 |
|a RC261
|b .H67 2012eb
|
| 072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Horizons in cancer research.
|n Volume 49 /
|c Hiroto S. Watanabe, editor.
|
| 260 |
|
|
|a Hauppauge, N.Y. :
|b Nova Science ;
|a Lancaster :
|b Gazelle [distributor],
|c 2012.
|
| 300 |
|
|
|a 1 online resource (xi, 239 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a HORIZONS IN CANCER RESEARCH. VOLUME 49 ; HORIZONS IN CANCER RESEARCH. VOLUME 49 ; Contents ; Preface; Endometrial Cancer: Diagnosis, Treatment and Prevention; Abstract; 1. Introduction; 2. Diagnosis of Endometrial Cancer; Symptoms and Screening; 3. Biomarkers Associated with Endometrial Cancer; 3.1. Oncogenes; 3.2. Tumour Suppressor Genes; 3.3. Microsatellite Instability (MSI); 3.4. MiroRNA; 3.5. Invasion and Migration; 3.6. Angiogenesis; 3.7. Endogenous Hormones and Endometrial Cancer; Steroid Hormones; Leptin and Adiponectin; Insulin, IGFs and SHBG; Growth Hormone Axis.
|
| 505 |
8 |
|
|a 3.8. Inflammatory MarkersCytokines; 4. Treatments; 4.1. Primary Surgery; 4.2. Adjuvant Treatments; 4.3. Novel Pathways and Targeted Therapies; Inhibiting Pathways of PI3-AKT-mTOR; EGFR Inhibitor and HER Family Inhibition; Antiangiogenics Agents; Cancer Stem Cells; 5. Prevention; Diet; Physical Activity; Conclusion; Acknowledgments; References; Liver Metastases of Colorectal Carcinoma: Magnetic Resonance Imaging Techniques and New Developments; Abstract; Introduction; Imaging; US, CT, PET(/CT); Magnetic Resonance Imaging; New Developments in MRI; Sequences for the Liver.
|
| 505 |
8 |
|
|a 1. Diffusion-Weighted Imaging (DWI)(Single Shot Spin Echo Echo Planar Imaging (SS SE-EPI Sequence))2. T1w Dynamic Contrast-Enhanced (DCE) MRI (4D THRIVE); Analysis of Tumour Heterogeneity: Region-of-Interest (ROI) Placements Versus Parametric (Pixel) Mapping; Magnetic Resonance Imaging Characteristics of "Hypovascular" Colorectal Liver Metastases; Usefulness of High B-Value DWI in Clinical Practice; Usefulness of DCE MRI in Clinical Practice; Conclusion; References; Can We Develop More Effective Combination Antiangiogenic Therapy for Patients with Cancer?; Abstract; Introduction.
|
| 505 |
8 |
|
|a Clinical Trials with Antiangiogenic Agents in HCC, Net, and RCC (Table I)Hepatocellular Carcinoma (HCC); Bevacizumab; Sunitinib; Sorafenib; Neuroendocrine Tumors (NET); Bevacizumab; Sunitinib; Renal Cell Carcinoma (RCC); Bevacizumab; Sunitinib; Sorafenib; Pazopanib; Other Antiangiogenic Agents; Mechanism of Resistance to Antiangiogenic Therapy; Rationale for Development of More Effective Antiangiogenic Therapy (Table II and Figure 1) ; References; Lung Metastases: Etiology, and Treatment; 1. Etiology; 1.1. Epithelial Tumors; Colorrectal Cancer; Breast Cancer; Gynaecological Cancer.
|
| 505 |
8 |
|
|a Renal CarcinomaMelanoma; Hepatocelular Carcinoma (HCC); Head and Neck Cancer; 1.2. Sarcomas; Osteosarcoma; Soft Tissue; 1.3. Germ Cell Tumors; 2. Prognostic Factors; 2.1. The Number of Pulmonary Metastases; Influence of the Number of Metastases on Survival; 2.2. Thoracic Lymphatic Involvement; What Is the True Incidence of Thoracic; Lymph Node Involvement?; What Is the Impact on Survival for Patients in Whom Pulmonary Metastases Have Themselves Metastasized to Lymph Nodes?; What Is Current Practice of Lymph Node; Assessment and Dissection?; 2.3. Special Primary Malignancies; Breast Cancer.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer.
|
| 650 |
|
2 |
|a Neoplasms
|
| 650 |
|
6 |
|a Cancer.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|2 fast
|
| 700 |
1 |
|
|a Watanabe, Hiroto S.
|
| 776 |
0 |
8 |
|i Print version:
|t Horizons in cancer research. Volume 49.
|d Hauppauge, N.Y. : Nova Science ; Lancaster : Gazelle [distributor], 2012
|z 9781619424050
|w (OCoLC)780334984
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=550440
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3021254
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10682766
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 550440
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 7312163
|
| 994 |
|
|
|a 92
|b IZTAP
|
